PMGC Holdings Inc.
ELAB evidence brief
What we can confirm
- BioSniper Score:
- 5.0 / 10
- Market Cap:
- $2.5M
- Lead Asset:
- el-22 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for ELAB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ELAB
PMGC Holdings Inc. (ELAB) is a holding company that, through its wholly owned subsidiary NorthStrive Biosciences, is developing engineered probiotic candidates EL-22 and EL-32 targeting muscle preservation in GLP-1 weight loss regimens, while also managing a multi-strategy investment vehicle and pursuing acquisitions.
Key risk: Early-stage pipeline
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$2.5M
Cash Runway
—
Lead Asset
el-22 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for PMGC Holdings Inc..
PMGC Holdings Inc. (ELAB) is a holding company that, through its wholly owned subsidiary NorthStrive Biosciences, is developing engineered probiotic candidates EL-22 and EL-32 targeting muscle preservation in GLP-1 weight loss regimens, while also managing a multi-strategy investment vehicle and pursuing acquisitions.
- PMGC reported total revenue of $1.3M and a net loss of -$2.9M for the period ended 2026-06-30 [sec].
- Shareholders' equity stood at $16.7M as of 2026-06-30 [sec].
- Lead candidates EL-22 and EL-32 are engineered probiotics designed to preserve muscle mass in combination with GLP-1 weight loss treatments; both are in preclinical development [pipeline].
- In September 2026, NorthStrive Biosciences engaged Charles River Laboratories for analytical characterization supporting IND-enabling development of EL-22 and EL-32 [news · 2026-09-29].
- PMGC announced a term sheet with Orbit2Orbit to launch a spaceflight study of EL-22 and EL-32 in microgravity [news · 2026-08-25].
What works
- NorthStrive has established partnerships with Charles River Laboratories, a leading CRO, to advance EL-22 and EL-32 toward IND-enabling development [news · 2026-09-29].
- The company is pursuing multiple value-creation avenues, including a multi-strategy investment vehicle (PMGC Capital LLC) and potential acquisitions of EBITDA-positive businesses [sec_mda · as of 2026-08-14].
- EL-22 and EL-32 target a large and growing market: muscle preservation in patients using GLP-1 weight loss drugs, a space where several major pharma companies are also active [pipeline].
What to weigh
- PMGC has minimal revenue ($1.3M as of 2026-06-30) and is operating at a net loss (-$2.9M), indicating it is still in a pre-revenue or early-revenue stage for its core programs [sec].
- Both EL-22 and EL-32 are in preclinical development, meaning they face years of clinical testing and regulatory hurdles before any potential commercialization [pipeline].
- The company's forward-looking statements explicitly caution that actual results may differ materially from current beliefs, and risk factors are detailed in its SEC filings [sec_mda · as of 2026-08-14].
From the filings
Quoted directly from source documents.
EL-22 and EL-32 are engineered probiotics for muscle preservation in GLP-1 weight loss
“Engineered probiotic expressing dual myostatin & activin-A”
NorthStrive engaged Charles River Laboratories for analytical characterization
“Engagement of a leading global contract research organization strengthens the analytical foundation supporting EL-22 and EL-32 as the programs advance toward an IND-enabling development framework”
News · September 29, 2026
PMGC plans a spaceflight study for EL-22 and EL-32
“PMGC Holdings Announces Term Sheet with Orbit2Orbit for NorthStrive Biosciences to Launch a Spaceflight Study of Its Myostatin and Activin A Assets, EL-22 and EL-32”
News · August 25, 2026
Risks & what to watch (3)›
Key risks
- Early-stage pipeline — Both lead candidates are preclinical; no IND filed, no clinical data generated [pipeline].
- Negative net income — Net loss of -$2.9M on only $1.3M revenue as of 2026-06-30 [sec].
- Forward-looking statement risk — SEC filings caution that actual results may differ materially from current beliefs [sec_mda · as of 2026-08-14].
What to watch
- Initiation of IND-enabling studies for EL-22 and EL-32 following the Charles River engagement [news · 2026-09-29].
- Outcome of the spaceflight study with Orbit2Orbit, which could provide unique microgravity data [news · 2026-08-25].
- Progress of the three-phase program with Yuva Biosciences to nominate a lead AI-discovered compound [news · 2026-09-01].
- Any new acquisitions or capital deployment by PMGC Capital LLC [sec_mda · as of 2026-08-14].
Sources: News · Pipeline · SEC MD&A · Generated October 4, 2026 · How we verify sources →
Run PMGC Holdings Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available PMGC Holdings Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.18
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
6
Total value held
$388K
| Holder | Shares | Value |
|---|---|---|
| jane street group, llc | 31,594 | $189K |
| morgan stanley | 15,000 | $90K |
| schonfeld strategic advisors llc | 14,800 | $89K |
| ifp advisors, inc | 2,000 | $12K |
| ubs group ag | 1,302 | $8K |
| tower research capital llc (trc) | 129 | $773 |
Short Interest
as of Apr 30, 2026- % of float
- 21.4%
- Days to cover
- 0.0
- Shares short
- 414,506
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ELAB short interestGovernance
Frequently asked questions
What is the AI investment thesis for PMGC Holdings Inc.?
PMGC Holdings Inc. (ELAB) is a holding company that, through its wholly owned subsidiary NorthStrive Biosciences, is developing engineered probiotic candidates EL-22 and EL-32 targeting muscle preservation in GLP-1 weight loss regimens, while also managing a multi-strategy investment vehicle and pursuing acquisitions.
What is PMGC Holdings Inc.'s lead drug candidate?
PMGC Holdings Inc.'s most advanced tracked candidate is el-22 (Phase 1) for Obesity (in combination with weight loss treatments to preserve muscle mass).
Who is the CEO of PMGC Holdings Inc.?
Mr. Graydon Bensler C.F.A. is the chief executive officer of PMGC Holdings Inc. (ELAB).
Where is PMGC Holdings Inc. headquartered?
PMGC Holdings Inc. (ELAB) is headquartered in Newport Beach, CA, United States.
What therapeutic areas does PMGC Holdings Inc. focus on?
PMGC Holdings Inc. develops therapies across Metabolic.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.